CLAIMS:

1. A polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by an X-ray diffraction pattern substantially similar to that set forth in FIG. 7.

2. A polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by an X-ray diffraction pattern including peaks at about 22.7, 19.7, 18.9 and 16.3 degrees 2θ.

3. A polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164, as measured by a Mettler 822^e DSC instrument.

4. The polymorph of claim 1, further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164, as measured by a Mettler 822^e DSC instrument.

5. The polymorph of claim 2, further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164, as measured by a Mettler 822^e DSC instrument.

6. The polymorph of any one of claims 1-3, produced by a purification process comprising the step of recrystallizing a crude preparation of said salt from acetone.

7. The polymorph of claim 6, wherein the amount of said acetone is greater than 64 volumes.

8. A pharmaceutical composition comprising the polymorph of any one of claims 1-3, and a pharmaceutically acceptable excipient or carrier.

9. A pharmaceutical composition according to claim 8 for use in the treatment of a disease or condition, wherein said disease or condition is selected from lung cancer, colon cancer, breast cancer, brain cancer, hearing loss, osteoporosis, obesity, diabetes, ophthalmic diseases, stroke, atherosclerosis, neuropathic pain, hepatitis B, and autoimmune disease.

10. A process for preparing the polymorph of any one of claims 1-3, comprising the step of adding methanesulfonic acid to 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide in acetone.

11. The process of claim 10, wherein the amount of said acetone is greater than 64 volumes.

12. The process of claim 11, wherein the amount of said acetone is greater than 64 and less than 100 volumes.

13. The process of claim 12, wherein the amount of said acetone is 80 volumes.

14. Use of the pharmaceutical composition of claim 8 in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of a disease or condition, wherein said disease or condition is selected from lung cancer, colon cancer, breast cancer, brain cancer, hearing loss, osteoporosis, obesity, diabetes, ophthalmic diseases, stroke, atherosclerosis, neuropathic pain, hepatitis B, and autoimmune disease.

What is claimed is:

1. A polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A) characterized by an X-ray diffraction pattern substantially similar to that set forth in FIG. 7.

2. A polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A) characterized by an X-ray diffraction pattern including peaks at about 22.7, 19.7, 18.9 and 16.3 degrees 20.

3. A polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A) characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164, as measured by a Mettler 822' DSC instrument.

4. The polymorph according to claim 1, further characterized by a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164, as measured by a Mettler 822' DSC instrument.

5. The polymorph according to claim 2, further characterized by a a Differential Scanning Calorimetry (DSC) thermogram having a single maximum value at about 164, as measured by a Mettler 822' DSC instrument.

6. The polymorph of claim 1 produced by a purification process comprising the step of recrystallizing a crude preparation of said salt from acetone.

7. The polymorph according to claim 6, wherein the amount of said acetone used is greater than 64 volumes.

8. A pharmaceutical composition comprising a polymorph according to claim 1 and a pharmaceutically acceptable excipient or carrier.

9. A process for preparing the polymorph according to claim 1 comprising the step of adding methanesulfonic acid to 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide in acetone.

10. The process according to claim 9, wherein the amount of said acetone is greater than 64 volumes.

11. The process according to claim 10, wherein the amount of said acetone is greater than 64 and less than 100 volumes.

12. The process according to claim 11, wherein the amount of said acetone is 80 volumes.